Dr. Reddy’s Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to Dr. Reddy’s revenue, but the company is preparing for a decline in sales as other generic versions enter the market.<\/p>\n
To mitigate this impact, Dr. Reddy’s is counting on its biosimilars business, which involves developing and marketing copies of biologic drugs. The company has a robust pipeline of biosimilars, including treatments for cancer, autoimmune disorders, and other diseases. Biosimilars have become a key growth driver for Dr. Reddy’s, with sales increasing by 25% in the last fiscal year.<\/p>\n
Another area of focus for Dr. Reddy’s is the rollout of its new weight-loss drug, which has shown promising results in clinical trials. The company is planning to launch the drug in the US market, where the demand for obesity treatments is high. Dr. Reddy’s is also exploring partnerships and collaborations to expand its reach in the global market.<\/p>\n
In addition to biosimilars and the weight-loss drug, Dr. Reddy’s is also investing in its generic business, with a focus on complex generics and injectables. The company has a strong presence in the US generic market and is looking to expand its portfolio of products.<\/p>\n
Dr. Reddy’s CEO, Erez Israeli, stated that the company is well-prepared for the loss of exclusivity for Revlimid and is confident about its growth prospects. He emphasized that the company’s diversified portfolio and strong research and development capabilities will help drive growth in the coming years.<\/p>\n
Overall, Dr. Reddy’s is taking a proactive approach to address the challenges posed by the expiration of its exclusivity for Revlimid. By focusing on biosimilars, the weight-loss drug, and its generic business, the company is positioning itself for long-term growth and success. With a strong pipeline of products and a commitment to innovation, Dr. Reddy’s is well-placed to maintain its position as a leading player in the global pharmaceutical industry. The company’s ability to adapt to changing market dynamics and its focus on emerging opportunities will be key to its success in the coming years.<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Reddy’s Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to Dr. Reddy’s revenue, but the […]<\/p>\n","protected":false},"author":1,"featured_media":88041,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-89836","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dr-reddys"],"jetpack_featured_media_url":"https:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89806,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/us-sales-of-revlimid-decline-offset-by-strong-domestic-market-growth\/","url_meta":{"origin":89836,"position":0},"title":"US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue\u2026","rel":"","context":"In "Cipla"","block_context":{"text":"Cipla","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/cipla\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Zydus-Logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89737,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/02\/usfda-deals-a-blow-to-dr-reddys-biosimilar-denosumab-avt03-following-an-inspection-of-the-manufacturing-facility\/","url_meta":{"origin":89836,"position":1},"title":"USFDA deals a blow to Dr Reddy’s biosimilar denosumab AVT03 following an inspection of the manufacturing facility.","author":"Team Small News","date":"January 2, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has faced a setback in its efforts to bring its denosumab biosimilar, AVT03, to the US market. The US Food and Drug Administration (USFDA) has issued a warning letter to the company after conducting an inspection of its manufacturing facility. The inspection revealed several issues with the\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89802,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/dr-reddys-introduces-generic-version-of-antihistamine-eye-drops-to-the-us-market\/","url_meta":{"origin":89836,"position":2},"title":"Dr Reddy’s introduces generic version of antihistamine eye drops to the US market","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89794,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/13\/dr-reddys-laboratories-has-been-issued-a-pre-approval-inspection-letter-from-the-usfda-for-its-biologics-facility-located-in-hyderabad\/","url_meta":{"origin":89836,"position":3},"title":"Dr. Reddy’s Laboratories has been issued a pre-approval inspection letter from the USFDA for its biologics facility located in Hyderabad.","author":"Team Small News","date":"January 13, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89705,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/25\/former-dr-reddys-facility-in-shreveport-gets-new-signage-frymaster\/","url_meta":{"origin":89836,"position":4},"title":"Former Dr. Reddy’s facility in Shreveport gets new signage: Frymaster.","author":"Team Small News","date":"December 25, 2025","format":false,"excerpt":"A new sign has been erected at the former Dr. Reddy's plant in Shreveport, indicating that Frymaster, a commercial fryer manufacturer, will be occupying the space. This development marks a significant turning point for the facility, which was previously home to Dr. Reddy's, a pharmaceutical company. The sign's installation suggests\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89748,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/04\/delhi-high-court-bars-dr-reddys-from-producing-venusia-sunscreens-bearing-the-sun-logo\/","url_meta":{"origin":89836,"position":5},"title":"Delhi High Court bars Dr Reddy’s from producing VENUSIA sunscreens bearing the SUN logo.","author":"Team Small News","date":"January 4, 2026","format":false,"excerpt":"The Delhi High Court has issued an interim order restraining Dr. Reddy's Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word \"SUN\". The court's decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy's is infringing on its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89836"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89836\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media\/88041"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}